Back Hepatitis C

Hepatitis C

EASL 2016: WHO Issues New Hepatitis C Guidelines, EASL Guidelines Update Coming

In April, coinciding with the International Liver Congress in Barcelona, the World Health Organization (WHO) released an update to its Guidelines for the Screening, Care and Treatment of Patients with Chronic Hepatitis C Infection. The guidelines promote the transition to newer, more effective direct-acting antiviral (DAA) medications that have the potential to cure most people living with hepatitis C. Also during the meeting the European Association for the Study of the Liver (EASL) announced it would update its hepatitis C treatment guidelines at a special conference in September.

alt

EASL 2016: Cost of Eliminating Viral Hepatitis Must Consider Social as Well as Medical Factors

Securing commitments from national governments to treat viral hepatitis, scale up prevention activities, and aim for elimination of hepatitis B and C by 2030 will require a broad coalition of forces -- and a sophisticated approach to proving the value of investing in elimination of viral hepatitis -- delegates heard at last month’s EASL International Liver Congress.

alt

EASL 2016: Portugal's Roll-Out of Hepatitis C DAA Therapy Achieves Impressive Outcomes

Roll-out of hepatitis C therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of treated patients had a sustained virological response (SVR) to therapy, with a 100% response rate seen in some sub-groups. Treatment also worked well for people with liver cirrhosis and treatment response was unaffected by HIV coinfection, previous hepatitis C therapy, or older age.

alt

Hepatitis C Kills More People than Any Other Infectious Disease, CDC Says

The number of deaths due to hepatitis C is at an all-time high in the U.S. and exceeds those attributable to 60 other infectious diseases including HIV and tuberculosis, according to new surveillance data released this week by the Centers for Disease Control and Prevention (CDC). However, a related Italian study found that hepatitis C patients who are successfully treated have a life expectancy similar to that of the general population.

alt

EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence

Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history of HCC, according to research presented at the recent European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona. These findings underline the importance of ongoing liver cancer monitoring even after successful hepatitis C treatment.

alt

EASL 2016: ABT-493 + ABT-530 Works Well for Patients Who Did Not Respond to Prior DAAs

An experimental combination of direct acting antivirals (DAAs) from AbbVie is effective and safe in patients with hepatitis C virus (HCV) genotype 1 who did not respond to previous DAA therapy, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona. Between 86% and 100% of patients achieved sustained virological response and the combination worked well in the context of pre-existing resistance mutations.

alt

EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for Genotype 3 Hepatitis C

A new combination of direct-acting antivirals developed by AbbVie -- ABT493 and ABT-530 -- is highly effective in curing people with genotype 3 hepatitis C virus (HCV) infection and liver cirrhosis, according to results from a pair of Phase 2 studies presented at last week’s EASL International Liver Congress (EASL 2016) in Barcelona.

alt

EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains

People on opiate substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier), leading to improvements in some aspects of quality of life, according to findings from the C-EDGE CO-STAR study presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona. However, the same study saw several cases of hepatitis C virus (HCV) reinfection after a cure, suggesting a greater emphasis on prevention may be warranted.

alt

EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings

Hepatitis C therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to U.S. research presented at the International Liver Congress in Barcelona last week. Investigators from the Department of Veteran Affairs (VA) analyzed outcomes in over 9000 patients treated with DAA combinations. Outcomes were excellent, with 2 combinations achieving cure rates of 93%, similar to those seen in randomized studies with strict eligibility criteria and close follow-up.

alt